drugset / Trial / NCT00002746
Interleukin-2 in Treating Patients With Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients with myelodysplastic syndrome.
Timeline
- Start
- 1996-01
- Primary completion
- 2004-04
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |